Mind Medicine (MindMed) (MNMD) to Release Quarterly Earnings on Thursday

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Mind Medicine (MindMed) to post earnings of ($0.33) per share for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.

Mind Medicine (MindMed) Stock Performance

Shares of MNMD traded up $0.02 during trading hours on Friday, hitting $6.72. The company's stock had a trading volume of 1,522,048 shares, compared to its average volume of 2,368,659. The business has a 50 day simple moving average of $7.50 and a two-hundred day simple moving average of $6.91. Mind Medicine has a 52-week low of $5.03 and a 52-week high of $12.22. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00. The company has a market cap of $492.79 million, a price-to-earnings ratio of -2.97 and a beta of 2.59.

Insider Activity

In other Mind Medicine (MindMed) news, CEO Robert Barrow sold 19,106 shares of the firm's stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $7.43, for a total transaction of $141,957.58. Following the sale, the chief executive officer now owns 526,666 shares in the company, valued at $3,913,128.38. This trade represents a 3.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dan Karlin sold 6,643 shares of Mind Medicine (MindMed) stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $7.43, for a total value of $49,357.49. Following the sale, the insider now directly owns 338,013 shares of the company's stock, valued at approximately $2,511,436.59. This trade represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,022 shares of company stock worth $208,203. 2.26% of the stock is currently owned by corporate insiders.

Remove Ads

Analyst Ratings Changes

Several research firms have issued reports on MNMD. HC Wainwright restated a "buy" rating and set a $55.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, January 31st. Chardan Capital began coverage on Mind Medicine (MindMed) in a report on Friday, December 20th. They set a "buy" rating and a $20.00 price objective on the stock. Evercore ISI assumed coverage on shares of Mind Medicine (MindMed) in a report on Tuesday, January 28th. They issued an "outperform" rating and a $23.00 price target on the stock. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $20.00 price objective on shares of Mind Medicine (MindMed) in a research note on Tuesday, December 17th. Ten investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $26.33.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.